Sanofi-a Ventis Deutschland Gmbh

Sanofi-aventis

Aventis Pharma Deutschland, Gmbh

Sanofi

Armin Bauer

Michael Wagner

Marc Nazare

Volkmar Wehner

Hans Matter

Matthias Urmann

Manfred Schudok

Anna Kohlmann

Volker Laux

Karl Schoenafinger

Elisabeth Defossa

Hubert Heuer

Andreas W Herling

David William Will

Stefan Petry

Thomas Klabunde

Stefan Peukert

Herman Schreuder

Alfons Enhsen

Martin Lorenz

Hans-Joerg Burger

Erich Von Roedern

Günter Müller

Bernd Neises

Karl Ulrich Wendt

Hubert Otto Heuer

The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.

Spirocyclic nitriles as protease inhibitors

The present invention relates to compounds of the formula I, which exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses.

Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors

The present invention relates to compounds of the formulae I and Ia, wherein R; R; R3; R4; R22, Q; V, G and M have the meanings indicated in the claims. The compounds of the formulae I and Ia are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formulae I and Ia, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Pyrrole-derivatives as factor Xa inhibitors

The present invention relates to a compound of the formula I wherein J, J, R, R, R, Q, V, G and M are as defined herein. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Indazole-derivatives as factor Xa inhibitors

This invention is directed to the compound of formula (I) which is useful for inhibiting the activity of Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as in inhibiting the formation of thrombin or for therapeutically or prophylactically treating a patient suffering from, or subject to, or associated with a disease state associated with a cardiovascular disorder.

Imidazole derivatives as factor Xa inhibitors

The present invention is directed to the compound of formula I which is useful for inhibiting the activity of blood clotting enzyme Factor Xa. The present invention is also directed to compositions containing said compounds, processes for their preparation, their use, such as for inhibiting the formation of thrombin or for therapeutically treating a patient suffering from, or subject to, a disease state associated with a cardiovascular disorder.

Triazole-derivatives as blood clotting enzyme factor Xa inhibitors

A substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-one, compound of formula 1,wherein R, R, R, Rand Rare as defined herein, pharmaceutical composition comprising the compound and use of the compound for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity are described.

Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof

Carboxamide-substituted phenylurea derivatives, process for their preparation and their use as medicaments

Growing community of inventors

Sulzbach, Germany

Armin Bauer